Navigation Links
MannKind Corporation to Host Webcast Analyst Day September 16, 2008
Date:9/11/2008

Company To Review Data from First Pivotal Phase 3 Clinical Trial

VALENCIA, Calif., Sept. 11 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that it will host an analyst day for the investment community to review clinical results from Phase 3 and other clinical trials of the company's Technosphere(R) Insulin System. The meeting will take place on Tuesday, September 16, 2008 from 9 a.m. to 11 a.m. Eastern Time in New York City. To access the live audio broadcast or the subsequent archived recording, please visit the MannKind Corporation web site at http://www.mannkindcorp.com.

Mr. Al Mann and other members of MannKind's management will review the Phase 3 data, and the meeting will also feature John ("Jack") E. Gerich, M.D., a world renowned diabetologist and expert in the physiology of diabetes and glucose metabolism. Dr. Gerich is professor of medicine and physiology and director of the clinical research center at the University of Rochester School of Medicine.

About the Technosphere(R) Insulin System

MannKind's investigational inhaled insulin product consists of its proprietary Technosphere(R) particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using MannKind's proprietary MedTone inhaler. A long sought-after goal in the treatment of diabetes has been to produce a profile of insulin levels in the bloodstream that closely mimics the normal human physiologic insulin response. In clinical studies to date, the Technosphere(R) Insulin System has been consistently observed to produce peak insulin levels within 12-14 minutes of inhalation, which approximates the early insulin secretion normally seen in healthy individuals following the beginning of a meal. MannKind believes that the ability to produce a better approximation of normal insulin physiology translates into better glucose control, thereby giving this investigational product potential clinical and commercial advantages.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes Technosphere(R) Insulin, which has completed Phase 3 clinical trials, and MKC253, which is currently in Phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MannKind Announces New $350 Million Credit Facility
2. MannKind to Present at Upcoming Conferences
3. MannKind Corporation Reports Third Quarter Financial Results
4. MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results
5. MannKind to Present at the Cowen and Company Healthcare Conference
6. The Leukemia & Lymphoma Society and MannKind Corporation Announce Collaborative Research Agreement
7. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
8. Brooke Franchise Corporation Announces Selected July Results
9. MedThink Communications Retained by NanoBio Corporation
10. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
11. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... RICHEY, Fla. (PRWEB) , ... April 24, 2017 ... ... and Prevention (CDC), rising prescription opioid overdose deaths now claim the lives of ... slashed its civil case filings against drug manufacturers, distributors, pharmacies and prescribers by ...
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively ... it is not known to have significant interactions with antiretroviral therapy (ART). ... cholesterol levels and dampen inflammation in the bloodstream. , While lowering cholesterol and ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads all sorts of ... of them to be very practical. She wanted to write a guide/workbook that would ... their health. It prompted her in writing “ A Clear Path to a Vibrant ...
(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, ... Trin, and Omega Station” is the creation of published author, Chris Jackson. Chris ... where he works in the Dallas Independent School District teaching English. He is heavily ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), ... ANCD BRAIN device as the product advances towards regulatory and clinical phases. , ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, the ... unveiled a new store design to enhance the ... healthier food, health-focused products and expanded beauty selections ... help customers discover new offerings. Together with its ... evolution of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
Breaking Medicine Technology: